nach oben

Infection

Erschienen in:

01.10.2011 | Clinical and Epidemiological Study

Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something?

verfasst von: O. K. Chan, T. T. Lao, S. S. H. Suen, T. K. Lau, T. Y. Leung

Erschienen in: Infection | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatitis B virus (HBV) infection is endemic in many countries, but the risk factors for HBV carriage in the obstetric population are unclear.

Methods

A survey on 1,580 women attending the antenatal clinic in an endemic region was conducted in order to examine the prevalence of and factors associated with maternal HBV carriage, including socio-demographic, medical, and previous obstetrical and family history, by means of a questionnaire.

Results

The prevalence of maternal HBV carriage was 9.1%, and 4.8% of women with a history of hepatitis B vaccination were found to be HBV carriers. Factors associated with maternal HBV carriage were residency status (adjusted odds ratio [aOR] 3.65 for immigrants; aOR 7.62 for non-residents), positive family history (aOR 3.72 for infected mother; aOR 5.36 for other family members), no previous vaccination (aOR 4.39) and having previous HBsAg testing (aOR 2.26).

Conclusions

The findings suggest that there was probably an overlooked role of horizontal transmission within the family setting in addition to perinatal transmission in determining the likelihood of HBV infection in our obstetric population. Reconfirmation of hepatitis B status might be necessary among individuals with a history of vaccination to ensure the effectiveness of their immunoprotection.

Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2:50–7.PubMed

World Health Organization (WHO). Hepatitis B. Fact sheet no. 204. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed 24 June 2011.

Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–56.PubMedCrossRef

Lee AK, Ip HM, Wong VC. Mechanisms of maternal–fetal transmission of hepatitis B virus. J Infect Dis. 1978;138:668–71.PubMedCrossRef

Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1:921–6.PubMedCrossRef

Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA. 1989;261:3278–81.PubMedCrossRef

Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapelière P, Safary A. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992;11:816–21.PubMedCrossRef

Lai CL, Wong BC, Yeoh EK, Lim WL, Chang WK, Lin HJ. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology. 1993;18:763–7.PubMedCrossRef

Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut. 1996;38:S39–42.PubMedCrossRef

10.

Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population—results of a 10-year study. J Infect Dis. 1997;175:674–7.PubMedCrossRef

11.

Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine. 2000;18:S35–8.PubMedCrossRef

12.

Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, Lu HC, Cheng SH, Wang YF, Wang CY, Lo KJ, Shih CJ, Sung JL. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA. 1988;260:2231–5.PubMedCrossRef

13.

Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, Bulkow LR, Wainwright RB. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413–8.PubMedCrossRef

14.

Kwan LC, Ho YY, Lee SS. The declining HBsAg carriage rate in pregnant women in Hong Kong. Epidemiol Infect. 1997;119:281–3.PubMedCrossRef

15.

Scientific Working Group on Viral Hepatitis Prevention. Recommendations on hepatitis B vaccination regimens in Hong Kong. Available from: http://www.info.gov.hk/hepatitis/english/group01_set.htm. Accessed 24 June 2011.

16.

Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol. 2007;47:46–50.PubMedCrossRef

17.

Suen SS, Lao TT, Sahota DS, Lau TK, Leung TY. Implications of the relationship between maternal age and parity with hepatitis B carrier status in a high endemicity area. J Viral Hepat. 2010;17:372–8.PubMedCrossRef

18.

Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine. 2007;25:6958–64.PubMedCrossRef

19.

Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust. 1997;166:127–30.PubMed

20.

Luksamijarulkul P, Mooktaragosa A, Luksamijarulkul S. Risk factors for hepatitis B surface antigen positivity among pregnant women. J Med Assoc Thai. 2002;85:283–8.PubMed

21.

Duong TH, Nguyen PH, Henley K, Peters M. Risk factors for hepatitis B infection in rural Vietnam. Asian Pac J Cancer Prev. 2009;10:97–102.PubMed

22.

Damale NK, Lassey AT, Bekoe V. Hepatitis B virus seroprevalence among parturients in Accra, Ghana. Int J Gynaecol Obstet. 2005;90:240–1.PubMedCrossRef

23.

Al Awaidy S, Abu-Elyazeed R, Al Hosani H, Al Mulla A, Al Busaiedy S, Al Amiry A, Farah Z, Al Marrie A, Bock HL, Al-Shaar I, Shah S. Sero-epidemiology of hepatitis B infection in pregnant women in Oman, Qatar and the United Arab Emirates. J Infect. 2006;52:202–6.PubMedCrossRef

24.

Chan OK, Suen SS, Lao TT, Leung VK, Yeung SW, Leung TY. Determinants of hepatitis B vaccine uptake among pregnant Chinese women in Hong Kong. Int J Gynaecol Obstet. 2009;106:232–5.PubMedCrossRef

25.

Wang H, Zhang W, Wu J, et al. Hepatitis B vaccination rate in adults of Beijing: a cross-sectional study. Chin J Public Health. 2010;26:612–4.

26.

Zeng XJ, Yang GH, Liao SS, Chen AP, Tan J, Huang ZJ, Li H. Survey of coverage, strategy and cost of hepatitis B vaccination in rural and urban areas of China. World J Gastroenterol. 1999;5:320–3.PubMed

27.

Zhou Y, Wang H, Zheng J, Zhu X, Xia W, Hipgrave DB. Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People’s Republic of China. Am J Trop Med Hyg. 2009;81:869–74.PubMedCrossRef

28.

Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J (Engl). 2007;120:2157–8.

29.

Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 1995;126:716–21.PubMedCrossRef

30.

Ayerbe MC, Pérez-Rivilla A; ICOVAHB Group. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol. 2001;17:150–6.PubMedCrossRef

31.

Zhou JJ, Wu WS, Sun CM, Dai HQ, Zhou N, Liu CB. Long-term evaluation of immune efficacy among newborns 16 years after HBV vaccination. Chin J Vaccin Immun. 2003;9:129–33.

32.

Lim WL, Wong DA, Cheng KC. Immune response to hepatitis B vaccine in health care workers in Hong Kong. HKMJ. 1996;2:138–40.

33.

Gerlich WH. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol. 2006;36:S18–22.PubMedCrossRef

34.

Ingardia CJ, Kelley L, Steinfeld JD, Wax JR. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol. 1999;93:983–6.PubMedCrossRef

35.

Jilg W, Schmidt M, Deinhardt F. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet. 1990;20:173–4.CrossRef

36.

Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol. 1987;126:492–9.PubMed

37.

Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr. 1993;16:66–9.PubMedCrossRef

38.

Chakravarty R, Chowdhury A, Chaudhuri S, Santra A, Neogi M, Rajendran K, Panda CK, Chakravarty M. Hepatitis B infection in Eastern Indian families: need for screening of adult siblings and mothers of adult index cases. Public Health. 2005;119:647–54.PubMedCrossRef

39.

Ucmak H, Faruk Kokoglu O, Celik M, Ergun UG. Intra-familial spread of hepatitis B virus infection in eastern Turkey. Epidemiol Infect. 2007;135:1338–43.PubMedCrossRef

40.

Talaat M, Radwan E, El-sayed N, Ismael T, Hajjeh R, Mahoney FJ. Case–control study to evaluate risk factors for acute hepatitis B virus infection in Egypt. East Mediterr Health J. 2010;16:4–9.PubMed

41.

Ben-Alaya-Bouafif N, Bahri O, Chlif S, Bettaieb J, Toumi A, Bel Haj HN, Zâatour A, Gharbi A, Dellagi K, Triki H, Ben Salah A. Heterogeneity of hepatitis B transmission in Tunisia: risk factors for infection and chronic carriage before the introduction of a universal vaccine program. Vaccine. 2010;28:3301–7.PubMedCrossRef

42.

Villarejos VM, Visoná KA, Gutiérrez A, Rodríguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med. 1974;291:1375–8.PubMedCrossRef

43.

Bancroft WH, Snitbhan R, Scott RM, Tingpalapong M, Watson WT, Tanticharoenyos P, Karwacki JJ, Srimarut S. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis. 1977;135:79–85.PubMedCrossRef

44.

Scott RM, Snitbhan R, Bancroft WH, Alter HJ, Tingpalapong M. Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis. 1980;142:67–71.PubMedCrossRef

45.

van der Eijk AA, Niesters HG, Götz HM, Janssen HL, Schalm SW, Osterhaus AD, de Man RA. Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol. 2004;29:92–4.PubMedCrossRef

46.

Kawsar M, Goh BT. Hepatitis B virus infection among Chinese residents in the United Kingdom. Sex Transm Infect. 2002;78:166–8.PubMedCrossRef

47.

Jeong SH, Yim HW, Yoon SH, Jee YM, Bae SH, Lee WC. Changes in the intrafamilial transmission of hepatitis B virus after introduction of a hepatitis B vaccination programme in Korea. Epidemiol Infect. 2010;138:1090–5.PubMedCrossRef

Titel: Correlation between maternal hepatitis B surface antigen carrier status with social, medical and family factors in an endemic area: have we overlooked something?
verfasst von: O. K. Chan
T. T. Lao
S. S. H. Suen
T. K. Lau
T. Y. Leung
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Infection / Ausgabe 5/2011
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-011-0151-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Immunogenicity of two different hepatitis B vaccine schedules

Community-onset bacteremia may be an ominous sign

Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese

Biliary tract infection caused by Vibrio fluvialis in an immunocompromised patient

Oral histoplasmosis of a healthy man in a non-endemic area